---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-006685"
form_type: "8-K"
ticker: "ATXI"
cik: "0001644963"
company_name: "AVENUE THERAPEUTICS, INC."
filed_at: "2025-03-07T23:59:59+00:00"
generated_at: "2026-05-25T03:44:33.315138+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Nasdaq grants Avenue Therapeutics continued listing exception; AnnJi seeks to terminate AJ201 license

## Summary
- Nasdaq Panel granted continued listing subject to: public disclosure by Mar 14, fundraising update by Mar 14, AJ201 trial results by Apr 15.
- AnnJi sent termination notice alleging material breaches of AJ201 license; Avenue believes claims are meritless and will contest.
- Avenue filed emergency arbitration to block AnnJi from unblinding clinical data in a way that would exhaust irreplaceable samples.
- Company must still regain compliance with stockholders' equity requirement; no assurance of success.

## SEC filing metadata
- accession: 0001437749-25-006685
- form_type: 8-K
- ticker: ATXI
- cik: 0001644963
- company_name: AVENUE THERAPEUTICS, INC.
- filed_at: 2025-03-07T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1644963/000143774925006685/0001437749-25-006685-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1644963/000143774925006685/atxi20250307_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-006685
- JSON: https://secwatch.observer/filing/0001437749-25-006685.json
- Plain text: https://secwatch.observer/filing/0001437749-25-006685.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.